Effective experience of treatment of diseases caused by human papillomaviruses in women of reproductive age

Despite primary and secondary prevention measures and the natural course of human papillomavirus infection, which provides a long latent phase during which its development can be prevented, cervical cancer (CC) is still diagnosed in more than 500,000 women worldwide each year. At the same time, approximately 90% of cervical cancer cases and deaths from it are recorded in low- and middle-income countries.According to current guidelines, cervical cancer screening (WHO, 2018, 2021, 2022) includes testing for the presence of human papillomavirus (HPV) to detect precancerous conditions with subsequent prescription of appropriate treatment, which determines the relevance of studies conducted using the original Ukrainian drug with a direct antiviral effect on papillomavirus – proteflazid, in particular in the form of suppositories for vaginal use.The objective: to analyze the experience of using proteflazid (suppositories and drops) for diseases of the genital organs in women of reproductive age caused by HPV.Materials and methods. An analysis of publications with data from clinical studies was conducted, in which over a ten-year period, approaches to the treatment and prevention of papillomavirus infection with the drug proteflazid (suppositories) in women with cervical intraepithelial neoplasia – CIN I and CIN II were studied and their effectiveness was evaluated.Results. Clinical studies have established high effectiveness of treatment with medications based on the active substance proteflazid CIN of mild and moderate degrees, while a low level of toxicity has been proven. This allows it to be used even during pregnancy and breastfeeding.Conclusions. Proteflazid (drops and suppositories) is currently a medication for specific antiviral therapy of HPV infection with the aim of eradicating the papillomavirus in women with cervical intraepithelial neoplasia (CIN I and CIN II) against the background of HPV infection and with a positive HPV test with a normal cytological picture.When treating cervical epithelial dysplasia caused by papillomavirus infection with proteflazid (suppositories), normalization of the cytological picture or the transition of cervical intraepithelial neoplasia of class CIN II (moderate dysplasia) to class CIN I (mild dysplasia) is determined.The drug proteflazid (suppositories) helps to eliminate dysbiotic disorders of the genital tract microflora, restores the normal biotope of the vagina, accelerates the processes of restoration of the epithelium of the mucous membrane of the cervix, prevents recurrence of diseases.